

WIN SYMPOSIUM 29-30 October 2022 Barcelona, Spain

INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY: A WINNING STRATEGY

Saturday October 29

WELCOME AND OPENING REMARKS			
08:30 (20')	Welcome and opening remarks	Richard L. Schilsky	Chairman WIN Consortium, Villejuif, France
		Josep Taberero	Vice-Chairman WIN Consortium, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
08:50 (30')	Opening Keynote Lecture Re-imagining the (r)evolution in the Precision Oncology paradigm: the future is now	Vivek Subbiah	The University of Texas, MD Anderson Cancer Center, Houston, USA
SESSION 1 - BEYOND DNA TESTING: THE PLACE OF TRANSCRIPTOMICS IN PRECISION ONCOLOGY			
09:20 (30')	Keynote Lecture Expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy	Louis M. Staudt	National Cancer Institute (NCI), Bethesda, USA
09:50 (30')	Keynote Lecture Functional genomics to identify cancer vulnerabilities	René Bernards	Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands
10:20 (30')	Accelerating precision oncology using multi-omics and AI	Olivier Elemento	Weill Cornell Medicine, New York, USA
10:50 (25')	<i>Coffee break, networking</i>		
11:15 (30')	Modeling gene regulatory processes to understand cancer and identify therapies	John Quackenbush	Harvard T.H. Chan School of Public Health, Boston, USA
11:45 (25')	SIMS and Digital Display Precision Predictor algorithms	Vladimir Lazar	WIN Consortium, Villejuif, France
12:10 (25')	Harnessing a synthetic lethality analysis for patient stratification: key role of transcriptomics	Eytan Ruppin	National Institute of Health (NIH), Bethesda, USA
12:35 (25')	Panel Discussion		
13:00 (30')	<i>Lunch, poster viewing and networking</i>		
SESSION 2 – INNOVATION IN CLINICAL TRIALS TO ENABLE FUTURE EFFICIENT TREATMENTS			
14:30 (25')	Keynote opening Lecture Bringing single cell analyses to the clinics	Andrea Califano	Columbia University Medical Center, New York, USA
14:55 (25')	Keynote lecture Identifying new uses for approved, targeted drugs: Updates from the ASCO TAPUR study	Richard L. Schilsky	WIN Consortium, Villejuif, France
15:20 (25')	Genomic and transcriptomic signatures and innovation in CRC cancers	Josep Taberero	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
15:55 (25')	Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses	Jean-François Martini	Pfizer, Inc., San Diego, USA
16:20 (25')	Patient stratification/selection for treatments with Tepotinib in the era of personalized medicine	Ilhan Celik	Merck KGaA, Darmstadt, Germany
16:45 (15')	<i>Coffee break, networking</i>		
18:00 (60')	Satellite Symposium		
18:30 (60')	<i>Poster viewing Welcome reception</i>		
20:00	<i>Symposium Dinner</i>		

SESSION 3 – DISRUPTIVE CONCEPTS AND METHODOLOGICAL INNOVATIONS IN NSCLC: MEET THE EXPERTS

08:30 (25')	Keynote lecture Advances in Lung Cancer	Solange Peters	President ESMO, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
08:55 (25')	Early stage lung cancer: challenge and opportunity	Haiquan Chen	Fudan University, Shanghai, China
09:20 (25')	Neoadjuvant and adjuvant strategies in NSCLC	Enriqueta Felip	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
09:45 (25')	A focus on emerging paradigms in the treatment of early NSCLC	Jair Bar	Chaim Sheba Medical Center, Ramat Gan, Israel
10:10 (25')	IO in combination: the SPRING trial tri-therapy approach	Benjamin Solomon	Avera Cancer Institute, Sioux Falls, USA
10:35 (25')	New drugs for SCLC	Fiona Blackhall	The Christie and Manchester Cancer Research Centre, Manchester, UK
11:00 (30')	<i>Coffee Break, networking</i>		

SESSION 4 - WIN FIRST INTERNATIONAL MOLECULAR TUMOR BOARD: A STRATEGIC PLACE IN ADVANCING PRECISION ONCOLOGY

11:30 (15')	First WIN International Molecular Tumor Board Introduction	Moderator Razelle Kurzrock	WIN Consortium, Villejuif, France
11:45 (50')	Patients' cases presentation by investigators. Discussion and treatment recommendation.		
12:35 (25')	Panel Discussion and Q&A from the audience		
13:00 (60')	<i>Lunch, poster viewing and networking</i>		

SESSION 5 – WHAT IS NEW IN BREAST, CRC, OVARY, HEAD & NECK, PROSTATE, KIDNEY, PEDIATRIC CANCERS?

14:00 (25')	Opening Keynote Lecture The BIG AURORA molecular screening program for metastatic breast cancer: first results	Martine Piccart	Institut Jules Bordet, Brussels, Belgium
14:25 (25')	Keynote Lecture Novel CRC insights based on combined genomic and transcriptomic data at both bulk and single cell level, leading to new therapeutically relevant CRC classification	Sabine Tejpar	University of Leuven, Belgium
14:50 (25')	Serial profiling in metastatic CRC; beyond the tip of the iceberg	Gerald Batist	Segal Cancer Centre, Lady Davis Institute at the JGH, McGill University, Montréal, Canada
15:15 (25')	Paradigm shift in treatment of ovarian cancers	Susan Galbraith	AstraZeneca, USA
15:40 (25')	Novel strategies in head & neck cancers	Christophe Le Tourneau	Institut Curie, Paris, France
16:05 (25')	Expanding Precision Oncology across tumor types: advances in prostate cancer	Joaquín Mateo	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
16:30 (25')	Pediatric European Precision Cancer Medicine Program - Facing cancer complexity	Birgit Geoerger	Gustave Roussy, Villejuif, France ITCC

16:55 (25')	BEST TWO POSTERS' PRESENTATIONS AND AWARDS Josep Tabernero, Vice-Chairman WIN Consortium, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain Amir Onn, Head of the Standard Operating Procedures and Repository Committee, WIN Consortium; Chair, Institute of Pulmonary Medicine, Sheba Medical Center, Israel		
----------------	---	--	--

17:20	CONCLUSIONS Richard L. Schilsky, Chairman WIN Consortium		
-------	--	--	--